A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT01733758 · Completed

Last updated 2026-05-28

This clinical trial tested two different doses of albiglutide, a medication, in Japanese adults with type 2 diabetes to see how it affects blood sugar levels over 24 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 494 people

Who can join Ages 20+ · all sexes

Timeline Started 2013-02 · est. completion 2015-02

Where 74 sites · Japan

What this study is testing ClinicalTrials.gov NCT01733758 ↗

Description as written by the study sponsor.

This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.

Treatments tested

Albiglutide 30 mg weekly Drug

Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
Albiglutide 50 mg weekly Drug

Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
Placebo Drug

Albiglutide matching placebo will be available as a pen injector
Liraglutide 0.9 mg daily Drug

Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose

Main thing measured	Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
Sponsor	GlaxoSmithKline
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01733758 ↗